Pherecydes Pharma reports successful patient treatment with bacteriophages

Phage therapy could offer an alternative treatment method in the fight against antimicrobial resistance

January 30, 2019
Pherecydes Pharma

Romainville, France, January 30, 2019 – Pherecydes Pharma, a biotechnology company specialized in the research and development of anti-infective therapies based on the use of bacteriophages, announces that its bacteriophage therapies have been successfully used to treat a patient with relapsing Staphylococcus aureus prosthetic-joint infection (PJI).


Full PR available here: